{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:45:58Z","timestamp":1781754358556,"version":"3.54.5"},"reference-count":34,"publisher":"LLC Obyedinennaya Redaktsiya","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ter. arkh."],"published-print":{"date-parts":[[2015]]},"DOI":"10.17116\/terarkh201587138-48","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T15:16:17Z","timestamp":1460646977000},"page":"38","source":"Crossref","is-referenced-by-count":18,"title":["Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter"],"prefix":"10.26442","volume":"87","author":[{"given":"E. B.","family":"Maykov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu. A.","family":"Yuricheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Yu.","family":"Mironov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. F.","family":"Sokolov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Golitsyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. V.","family":"Rozenshtraukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. I.","family":"Chazov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18344","reference":[{"key":"key-10.17116\/terarkh201587138-48-1","doi-asserted-by":"crossref","unstructured":"Stewart S., Hart C.L., Hole D.J., McMurray J.J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew\/Paisley study. Heart 2001; 86: 516\u2014521.","DOI":"10.1136\/heart.86.5.516"},{"key":"key-10.17116\/terarkh201587138-48-2","doi-asserted-by":"crossref","unstructured":"Go A.S., Hylek E.M., Phillips K.A. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370\u20142375.","DOI":"10.1001\/jama.285.18.2370"},{"key":"key-10.17116\/terarkh201587138-48-3"},{"key":"key-10.17116\/terarkh201587138-48-4","doi-asserted-by":"crossref","unstructured":"Benjamin E.J., Wolf P.A., D\u2019Agostino R.B. et al. Impact of atrial fibrillation in the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946\u201452.","DOI":"10.1161\/01.CIR.98.10.946"},{"key":"key-10.17116\/terarkh201587138-48-5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs253"},{"key":"key-10.17116\/terarkh201587138-48-6","unstructured":"Roy D., Pratt C., Juul-M\u04e6ller S. et al., on behalf of the ACT III Investigators. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a phase III, randomized, placebo-controlled, multicenter trial. (Abstract). J Am Coll Cardiol 2006; 47: 10A."},{"key":"key-10.17116\/terarkh201587138-48-7","doi-asserted-by":"crossref","unstructured":"Roy D., Pratt C.M., Torp-Pedersen C. et al., for the Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008; 117: 1518\u20141525.","DOI":"10.1161\/CIRCULATIONAHA.107.723866"},{"key":"key-10.17116\/terarkh201587138-48-8","doi-asserted-by":"crossref","unstructured":"Kowey P.R., Dorian P., Mitchell L.B. et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009; 2: 652\u2014659.","DOI":"10.1161\/CIRCEP.109.870204"},{"key":"key-10.17116\/terarkh201587138-48-9","doi-asserted-by":"crossref","unstructured":"Camm A.J., Capucci A., Hohnloser S. et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent onset atrial fibrillation. J Am Coll Cardiol 2011; 57 (3): 313\u2014321.","DOI":"10.1016\/j.jacc.2010.07.046"},{"key":"key-10.17116\/terarkh201587138-48-10","unstructured":"Rozenshtraukh L.V., Anyukhovskii E.P., Beloshapko G.G. i dr. Elektrofiziologicheskie aspekty kardiotropnogo deistviya novogo antiaritmicheskogo preparata nibentana (eksperimental'noe issledovanie). Kardiologiya 1995; 5: 25\u201436."},{"key":"key-10.17116\/terarkh201587138-48-11","unstructured":"Bregvadze I.N., Maikov E.B., Sokolov S.F. i dr. Effektivnost' i bezopasnost' nibentana pri medikamentoznoi kardioversii u bol'nykh s persistiruyushchei formoi fibrillyatsii i trepetanii predserdii: rol' ogranicheniya doz preparata i primeneniya magniya sul'fata. Kardiologiya 2007; 3: 48\u201455."},{"key":"key-10.17116\/terarkh201587138-48-12","unstructured":"Bregvadze I.N., Maykov E.B., Sokolov S.F. et al. The efficacy and safety of new III class antiarrhythmic drug nibentan for Cardioversion in patients with persistent atrial fibrillation. Congress of European Society of cardiology. Barcelona 2006 Sep. Eur Heart J 2006; Suppl 27: 887."},{"key":"key-10.17116\/terarkh201587138-48-13","unstructured":"Reznik A.V., Fedorov V.V., Kokoz Yu.M. i dr. Ionnye mekhanizmy kardiotropnogo deistviya preparata III klassa RG-2. Kardiologiya 2003; 10: 76\u201482."},{"key":"key-10.17116\/terarkh201587138-48-14","unstructured":"Fedorov V.V., Ivanova A.I., Glukhov A.V. i dr. Kholinoliticheskaya aktivnost' antiaritmicheskogo preparata III klassa RG-2. Kardiologiya 2004; 7: 62\u201466."},{"key":"key-10.17116\/terarkh201587138-48-15","unstructured":"Fedorov V.V., Rozenshtraukh L.V., Reznik A.V. i dr. Antiaritmicheskaya aktivnost' preparata III klassa RG-2 na vagotonicheskoi modeli fibrillyatsii predserdii. Kardiologiya 2004; 11: 66\u201474."},{"key":"key-10.17116\/terarkh201587138-48-16","unstructured":"Mironov N.Yu., Golitsyn S.P., Sokolov S.F. i dr. Elektrofiziologicheskie i antiaritmicheskie effekty novogo otechestvennogo antiaritmicheskogo preparata III klassa niferidila. Soobshchenie I: elektrofiziologicheskie effekty niferidila u bol'nykh paroksizmal'nymi nadzheludochkovymi takhikardiyami. Vestn aritmol 2012; 70: 5\u201413."},{"key":"key-10.17116\/terarkh201587138-48-17","doi-asserted-by":"crossref","unstructured":"Lepeshkin E., Suravicz B. The measurement of the QT interval of the electrocardiogram. Circulation 1952; 6: 378\u2014388.","DOI":"10.1161\/01.CIR.6.3.378"},{"key":"key-10.17116\/terarkh201587138-48-18","doi-asserted-by":"crossref","unstructured":"Velebit V., Podrid P.J., Lown B. et al. Aggravation and provocation of ventricular arrhythmia by antiarrhythmic drugs. Circulation 1982; 65: 886\u2014894.","DOI":"10.1161\/01.CIR.65.5.886"},{"key":"key-10.17116\/terarkh201587138-48-19","doi-asserted-by":"crossref","unstructured":"Falk R.H., Knowlton A.A., Bernard S.A. et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med 1987; 106: 503\u2014506.","DOI":"10.7326\/0003-4819-106-4-503"},{"key":"key-10.17116\/terarkh201587138-48-20","unstructured":"Fedorov V.V., Sharifov O.F., Rozenshtraukh L.V. i dr. Mekhanizm antiaritmicheskogo deistviya nibentana na eksperimental'noi modeli vagotonicheskoi fibrillyatsii predserdii. Kardiologiya 1999; 3: 45\u201457."},{"key":"key-10.17116\/terarkh201587138-48-21","doi-asserted-by":"crossref","unstructured":"Fedorov V.V., Sharifov O.F., Beloshapko G.G. et al. Effects of new class III antiarrhythmic drug nibentan ina canine model of vagally mediated atrial fibrillation. J Cardiovasc Pharmacol 2000; 36 (1): 77\u201489.","DOI":"10.1097\/00005344-200007000-00011"},{"key":"key-10.17116\/terarkh201587138-48-22","doi-asserted-by":"crossref","unstructured":"Olshansky B., Wilber D.J., Hariman R.A. Atrial flutter: update on the mechanism and treatment. PACE 1992; 15: 2308\u20142336.","DOI":"10.1111\/j.1540-8159.1992.tb04174.x"},{"key":"key-10.17116\/terarkh201587138-48-23","doi-asserted-by":"crossref","unstructured":"Cardiology. The Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831\u20141851.","DOI":"10.1161\/01.CIR.84.4.1831"},{"key":"key-10.17116\/terarkh201587138-48-24","doi-asserted-by":"crossref","unstructured":"Murray K.T. Ibutilide. Circulation 1998; 97: 493\u2014497.","DOI":"10.1161\/01.CIR.97.5.493"},{"key":"key-10.17116\/terarkh201587138-48-25","doi-asserted-by":"crossref","unstructured":"Falk R.H., Pollak A., Singh S.N., Freidrich T. Intravenous dofetilide, a class III antiarrhythmic agent for termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997; 29: 385\u2014390.","DOI":"10.1016\/S0735-1097(96)00506-2"},{"key":"key-10.17116\/terarkh201587138-48-26","doi-asserted-by":"crossref","unstructured":"Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs 2007; 16: 1034\u20141049.","DOI":"10.1517\/13543784.16.4.519"},{"key":"key-10.17116\/terarkh201587138-48-27","doi-asserted-by":"crossref","unstructured":"Savelieva I., Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 2008; 10: 647\u2014655.","DOI":"10.1093\/europace\/eun130"},{"key":"key-10.17116\/terarkh201587138-48-28","doi-asserted-by":"crossref","unstructured":"Echrlich J.R., Biliczki P., Hohnloser S.H., Nattel S. Atrial-selective approaches for the treatment of atrial fibrillation. J Am Coll Cardiol 2008; 51: 787\u2014792.","DOI":"10.1016\/j.jacc.2007.08.067"},{"key":"key-10.17116\/terarkh201587138-48-29","doi-asserted-by":"crossref","unstructured":"Camm A.J., Cappucci A., Hohnloser S.H., Torp-Pedersen C. and AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011; 57 (3): 313\u2014321.","DOI":"10.1016\/j.jacc.2010.07.046"},{"key":"key-10.17116\/terarkh201587138-48-30","unstructured":"Egorov Yu.V., Stolbova V.I., Kuz'min V.S., Rozenshtraukh L.V. Vliyanie antiaritmicheskogo preparata III klassa niferidila (RG-2) na bioelektricheskuyu aktivnost' miokarda legochnykh ven. Kardiologiya 2012; 2: 47\u201451."},{"key":"key-10.17116\/terarkh201587138-48-31","doi-asserted-by":"crossref","unstructured":"Crystal E., Kahn S., Roberts R. et al. Long-term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). J Thorac Cardiovasc Surg 2003; 125: 633\u2014637.","DOI":"10.1067\/mtc.2003.9"},{"key":"key-10.17116\/terarkh201587138-48-32","doi-asserted-by":"crossref","unstructured":"Pratt C.M., Al Khalidi H.R., Brum J.M. et al. Cumulative experience of azimilide-associated torsade de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. J Am Coll Cardiol 2006; 48: 471\u2014477.","DOI":"10.1016\/j.jacc.2006.04.075"},{"key":"key-10.17116\/terarkh201587138-48-33","doi-asserted-by":"crossref","unstructured":"Shantsila E., Watson T., Lip G. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. Europace 2007; 9 (suppl 4): iv37\u2014iv44.","DOI":"10.1093\/europace\/eum169"},{"key":"key-10.17116\/terarkh201587138-48-34","doi-asserted-by":"crossref","unstructured":"Roden D.M., Kannankeril P., Darbar D. On the relationship among QT interval, atrial fibrillation, and torsade de pointes. Europace 2007; 9 (suppl 4): iv1\u2014iv3.","DOI":"10.1093\/europace\/eum165"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T21:23:47Z","timestamp":1593379427000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/terapevticheskij-arkhiv\/2015\/1\/downloads\/ru\/250040-36602015016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"alternative-id":["terarkh201587138-48"],"URL":"https:\/\/doi.org\/10.17116\/terarkh201587138-48","relation":{},"ISSN":["0040-3660"],"issn-type":[{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}